CD83, a maturation marker for human and mouse dendritic cells (DCs), plays a critical role in CD4+ T cell development as well as peripheral immune regulation. Here, two novel mouse anti-human CD83 monoclonal antibodies (MAbs) were prepared and their immunological characteristics were determined. Among the two MAbs, 8B4 binds to a linear epitope whereas 1E11 recognizes a conformational epitope. Cross-linking of 8B4 but not 1E11 with CD83-Ig augments the fusion protein mediated inhibition of peripheral blood mononuclear cells (PBMCs). Thus the two MAbs may be good candidates for immunoassaying and functional exploration of CD83 molecule.
Get full access to this article
View all access options for this article.
References
1.
ZhouLJ, SchwartingR, SmithHM, TedderTF. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J Immunol, 1992; 149,2:735–742.
2.
ZhouLJ, TedderTF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol, 1995; 154:3821–3835.
3.
TwistCJ, BeierDR, DistecheMC, EdelhoffS, TedderTF. The mouse CD83 antigen: structure, domain organization and chromosome localization. Immunogenetics, 1998; 48:383–393.
4.
LechmannM, KrooshoopDJ, DudziakD, KremmerE, KuhntC, FigdorCG, SchulerG, SteinkassererA. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a counter receptor on dendritic cells. J Exp Med, 2001; 194:1813–1821.
5.
SchollerN, Hayden-LedbetterM, HellströmKE, HellstromI, LedbetterJA. CD83 is a sialic acid-binding Ig-like lectin (Siglec) adhesion receptor that binds monocytes and a subset of activated CD8+ T cells. J Immunol, 2001; 166,6:3865–3872.
6.
HockBD, KatoM, McKenzieJL, HartDN. A soluble form of CD83 is released from activated dendritic cells, B lymphocytes, is detectable in normal human sera. Int Immunol, 13:959–967.
7.
HockBD, HaringLF, SteinkassererA, TaylorKG, PattonWN, McKenzieJL. The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leuk Res, 2004; 28,3:237–241.
8.
HockBD, FernyhoughLJ, GoughSM, SteinkassererA, CoxAG, McKenzieJL. Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leuk Res, 2009; 33:1089–1095.
9.
HockBD, O'DonnellJL, TaylorK, SteinkassererA, McKenzieJL, RothwellAG, SummersKL. Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients. Tissue Antigens, 2006; 67,1:57–60.
10.
FujimotoY, TuL, MillerAS, BockC, FujimotoM, DoyleC, SteeberDA, TedderTF. CD83 expression influences CD4+ T cell development in the thymus. Cell, 2002; 108:755–767.
11.
SenechalB, BoruchovAM, ReaganJL, HartDN, YoungJW. Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood, 2004; 103:4207–4215.
12.
CramerSO, TrumpfhellerC, MehlhoopU, MoréS, FleischerB, von BoninA. Activation-induced expression of murine CD83 on T cells and identification of a specific CD83 ligand on murine B cells. Int Immunol, 2000; 12,9:1347–1351.
13.
LechmannM, KotzorN, ZinserE, PrechtelAT, StichtH, SteinkassererA. CD83 is a dimer: comparative analysis of monomeric and dimeric isoforms. Biochem Biophys Res Commun, 2005; 329:132–139.
14.
DudziakD, NimmerjahnF, BornkammG.W, LauxG. Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation. J Immunol, 2005; 174:6672–6676.
15.
ZinserE, LechmannM, GolkaA, LutzMB, SteinkassererA. Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83. J Exp Med, 2004; 200:345–351.
16.
XuJF, HuangBJ, YinH, XiongP, FengW, XuY, FangM, ZhengF, WangCY, GongFL. A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts. Transpl Int, 2007; 20,3:266–276.
17.
WangJM, LiF, ZhangGB, ChenYJ, HuYM, ChenXQ, LuBF, ZhangXG. Two novel monoclonal antibodies against human CD133-2: distinct epitopes and agonist activity to enhance growth of CD133 expression cells in vitro. Hybridoma, 2010; 29,3:241–249.
